TABLE 1.
Epitope specificity and neutralization activity of the anti-HIV-1 monoclonal antibodies used in this study
| Antibody | Epitope | Reference | Neutralization IC50 (μg/ml) |
||
|---|---|---|---|---|---|
| NL4.3 | NLAD8 | CH058 | |||
| nnAbs | |||||
| 5-25 | gp41 immunodominant | 20 | >15 | >15 | >15 |
| 4-20 | gp41 immunodominant | 20 | >15 | >15 | >15 |
| 4-42 | CD4-induced CoRBS | 20 | 0.1 | >15 | >15 |
| 4-8 | CD4-induced CoRBS | 20 | 1.1 | >15 | >15 |
| 2-1262 | CD4 binding site | 20 | 0.24 | >15 | >15 |
| 1-863 | CD4 binding site | 20 | 0.84 | >15 | >15 |
| 2-59 | V3 crown | 20 | >15 | >15 | >15 |
| 10-188 | V3 crown | 28 | >15 | >15 | >15 |
| 11-340 | V3 crown | 28 | >15 | >15 | >15 |
| bNAbs | |||||
| 3BNC117 | CD4 binding site | 29 | 0.05 | 0.1 | 0.1 |
| NIH45-46 | CD4 binding site | 29 | 0.06 | 0.2 | 0.2 |
| 10-1074 | N322-glycan supersite | 27 | >15 | 0.1 | 0.2 |
| PGT128 | N322-glycan supersite | 73 | >15 | 0.2 | 0.02 |
| PG16 | V1/V2 glycans | 74 | 0.7 | 0.05 | >15 |